Cortexyme Loses 70% Of Its Value On Missed Alzheimer's Test — But There's A Caveat

Cortexyme Loses 70% Of Its Value On Missed Alzheimer's Test — But There's A Caveat

Submitted by admin on October 26, 2021 - 11:45pm
Source: 
Investors Business Daily
News Tags: 
Cortexyme
Alzheimer's disease
clinical trials
atuzaginstat
Headline: 
Cortexyme Loses 70% Of Its Value On Missed Alzheimer's Test — But There's A Caveat
snippet: 

Cortexyme (CRTX) said Tuesday it narrowed the pool for its Alzheimer's drug after only certain patients responded to the twice-daily pill. But CRTX stock crashed on the results.

Do Not Allow Advertisers to Use My Personal information